APTEVO THERAPEUTICS INC. — Key Metrics
9 years of history · ending 2022-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$2
Book Value Per Share
$4
Free Cash Flow Per Share
$-4
Cash Per Share
$4
Revenue Per Share
$1
OCF Per Share
$-4
Return on Equity↑+179.2pts
83.7%
Return on Assets↑+75.9pts
17.7%
Return on Invested Capital↓-130.5pts
-185.8%
Debt to Equity↓-87.2% -$1
0.08
Current Ratio↑+14.0% +$0
3.15
Quick Ratio↑+18.4% +$0
3.15
Asset Turnover↓-72.6% -$0
0.07
Days Sales Outstanding
79.05
Days Payables Outstanding
117.72
Days Inventory On Hand
112.45
Cash Conversion Cycle
73.77
R&D / Revenue↑+420.8pts
574.2%
SBC / Revenue↑+48.6pts
57.9%
Capex / Revenue↓-3.3pts
0.9%
Working Capital↓-39.7% -$12M
$19M
Net Current Asset Value↓-3.4% -$392K
$11M
Invested Capital↓-60.9% -$30M
$19M
OCF / Net Income↓-373.4% -$4
-2.62
FCF / Net Income↓-368.7% -$4
-2.62
Accruals Ratio (Sloan)↑+88.3pts
84.9%
Net Debt↓-86.5% -$10M
$-21M
Net Debt / EBITDA↑+231.3% +$1
0.76
Capex Coverage↓-1275.9% -$672
-724.90
Tangible Common Equity↓-28.5% -$7M
$18M
TCE / Total Assets↑+15.3pts
52.5%
Goodwill / Total Assets
22.9%
NOPAT↑+44.6% +$18M
$-23M
Cash ROIC↓-101.8pts
-172.9%
WC / Revenue↑+467.2pts
601.9%
Capex / D&A↓-92.1% -$0
0.03
Reinvestment Rate↑+0.3pts
3.0%
Asset Growth vs Revenue Growth↑+134.8pts
35.1%
Revenue 5Y CAGR
-26.6%
EPS 5Y CAGR
2.9%
Book Value 5Y CAGR
-26.2%
Stock Price (FY-end)↓-87.0% -$9M
$1M
Market Cap
$6.9T
P/E Ratio
864390.29
P/S Ratio
2228150.57
P/B Ratio
386027.64
P/TB Ratio
386027.64
Enterprise Value
$6.9T
EV / Sales
2228143.77
FCF Yield
-0.0%
Shareholder Yield
-0.0%
R&D Yield
0.0%
Capex Yield
0.0%
Graham Number
$11
Shares Variation (YoY)
8.9%
Beta (5Y)↓-10.1% -$0
1.13
Cost of Equity↓-0.6pts
10.1%
52W High↓-89.9% -$44M
$5M
52W Low↓-88.5% -$9M
$1M
Trailing Return 1Y↓-0.7pts
-70.7%
Trailing Return 5Y
-96.1%
F-Score (Piotroski)↑+100.0% +$2
4.00
M-Score (Beneish)
-1.41
Z-Score (Altman)
256320.85
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.